Navigation Links
Oncothyreon reports full year and fourth quarter 2007 financial results
Date:3/10/2008

BELLEVUE, WA, March 10 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY) (the "Company") today reported financial results for the year and quarter ended December 31, 2007. All results are in U.S. dollars and prepared using U.S. GAAP.

Net loss for the year ended December 31, 2007, was $20.3 million or $1.04 per basic and diluted share, compared with $36.4 million, or $2.38 per basic and diluted share in 2006. The substantial decrease in net loss when compared with 2006 primarily reflects the charge of $24.9 million in 2006 related to the acquisition of ProlX Pharmaceuticals, Inc. General and administrative expenses increased by $4.2 million for the year ended December 31, 2007, compared with the year ended December 31, 2006, primarily due to costs associated with the Company's reincorporation into the United States and certain costs associated with a reduction in administrative staff. Revenue from operations for the year ended December 31, 2007, was $3.8 million, compared to $4.0 million in the prior year.

Net loss for the quarter ended December 31, 2007, was $5.2 million or $0.26 per basic and diluted share, compared with $27.1 million or $1.58 per basic and diluted share for the comparable period in 2006. Revenue from operations was $1.9 million, compared to $1.1 million for the same period in 2006. Expenses for the quarter were $7.1 million, compared with $28.7 million for the comparable period in 2006, which included charges of $24.9 million relating to the October 2006 acquisition of ProlX.

As of December 31, 2007, Oncothyreon's cash, cash equivalents and short-term investments were $24.2 million, compared to $28.4 million at the end of 2006, a decrease of $4.2 million, or 14.8 percent. The net d
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
2. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
3. Oncothyreon launches new corporate website
4. Oncothyreon to present at BIO CEO & Investor Conference
5. Oncothyreon highlights corporate and clinical objectives for 2008
6. Biomira announces plan to change name to Oncothyreon
7. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
8. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
9. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
10. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
11. ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... (PRWEB) October 30, 2014 2014 ... HCL Industry” is a professional and in-depth research ... provides basic Naltrexone HCL information, including its definition, ... as industry overview. This research covers the international ... as global industry analysis covering macroeconomic environment & ...
(Date:10/30/2014)... 2014 SoundConnect , an ... Office 365 end users the key to turning ... system by adding voice enablement and hybrid audio ... Online, a communication tool that includes presence, instant ... voice, O365 becomes a comprehensive unified communications solution. ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 James Sherley says ... in adult tissue stem cell technology since his days as ... in Philadelphia in the late 1990’s. Sherley founded the ... The company holds all the intellectual property developed in Sherley’s ... at the Massachusetts Institute of Technology (MIT), and more recently ...
(Date:10/30/2014)... 2014 Whitehouse Laboratories has formally announced ... Testing and Package Test Capacity. Responding to growing demands ... dramatic increase in environmental chamber storage space that will ... aging samples to be securely held on site at ... expenditure has already taken place with the recent completion ...
Breaking Biology Technology:Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 2Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 3SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 2SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 2Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 4Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 3
... CRANBURY, N.J., Feb. 18, 2011 Palatin Technologies, Inc. (NYSE ... and webcast on February 24, 2011 at 11:00 a.m. Eastern ... results and plans for its programs under development.   ... Call / Webcast Q2 Fiscal Year 2011 Conference Call-Live ...
... have heard of virtual keyboards controlled by thought, brain-powered ... be downright tiring, a fact that prevents the technology ... among others. Professor Jos del R. Milln and his ... in Switzerland have a solution: engineer the system so ...
... Pharmaceuticals, Inc. (Nasdaq: SVNT ) today announced that ... at the Citi 2011 Global Healthcare Conference on Tuesday, March ... be held at the New York Hilton in New York, ... can be accessed through the investor relations section of the ...
Cached Biology Technology:Taking brain-computer interfaces to the next phase 2
(Date:10/31/2014)... synchrotron source that emits over a wide part of ... is currently being built in Lund, Sweden. The MAX ... the team putting together its component parts in a ... circumference of just a few hundred metres. Nevertheless, if ... new class of experiments that require source brightness and ...
(Date:10/31/2014)... steps involved in programmed cell death, offering new targets ... neurodegenerative diseases. , The research teams from the ... the three-dimensional structure of a key cell death protein ... it causes cell death. Their studies were published in ... Proceedings of the National Academy of Sciences . ...
(Date:10/30/2014)... a $1.04 million grant from the U.S. Army ... osteoarthritis using a patient,s own stem cells, spurred ... polymers., Liping Tang, a bioengineering professor and interim ... is primarily focused on helping soldiers who are ... if we inject microscaffolding that we,ve developed into ...
Breaking Biology News(10 mins):A new generation of storage -- ring 2A matter of life and death: Cell death proteins key to fighting disease 2UTA researcher uses microscaffolding injections to mend cartilage, prevent osteoarthritis 2
... available in French . , A new ... University reveals that ghrelin - a stomach hormone, acts on ... food related cues and eating for pleasure. This study, ... critical to advance understanding and treating obesity, a condition affecting ...
... There are two ways in which cooperation is the theme ... Mary Anne Alliegro, scientists at the Marine Biological Laboratorys (MBL) ... the papers acknowledgements, where the Alliegros thank those who helped ... State University (LSU) in New Orleans and their lives ...
... N.Y., May 5 bioMETRX Inc., (OTC,Bulletin Board: ... products, today announced that it has closed an ... group of previous angel,accredited investors., "We have ... team.,The company has demonstrated to us the ability ...
Cached Biology News:Hunger hormone: Makes food more attractive 2The cooperative view: New evidence suggests a symbiogenetic origin for the centrosome 2bioMETRX, Inc. Closes Angel Round of Funding 2
... APAgene kits are designed to rapidly ... using our patented APA Technology. ... at an extraordinarily competitive price. All ... kit. The Locator Kit can be ...
Recommended for supporting the growth of anchorage-dependent cells including human and mouse stromal cells, mesenchymal cells and cell lines....
... This CLS number is a ... easily match Cornings product number. ... please order under the old ... customer service for assistance. ID ...
Extremely high efficiency packaging extracts useful for transfecting our EpiFOS™ or CopyControl™ Fosmids, or any DNA vector with cos sites. A tremendous value when conpared to the competition...
Biology Products: